Frequently Asked Questions
The global chronic bronchitis market is projected to grow at a CAGR of 4.0% during the forecast period of 2022-2029.
Factors such as growing demand for combination therapy and increasing prevalence of COPD are acting as the major drivers for the global chronic bronchitis market.
The major countries covered in the global chronic bronchitis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
The major players operating in the market are Bayer AG (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Sun Pharmaceutical Industries Ltd. (India), Hikma Pharmaceutical PLC (U.S.), Amneal Pharmaceuticals LLC. (U.K.), Aurobindo Pharma (India), Johnsons & Johnsons Private limited (U.S.) and GlaxoSmithKline Plc (U.S.).
